Sei Investments Co. Purchases New Position in BioAge Labs, Inc. $BIOA

Sei Investments Co. acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 62,385 shares of the company’s stock, valued at approximately $1,091,000. Sei Investments Co. owned about 0.14% of BioAge Labs at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Militia Capital Management LLC acquired a new position in shares of BioAge Labs during the 1st quarter worth $565,000. Dimensional Fund Advisors LP acquired a new stake in shares of BioAge Labs in the first quarter valued at about $3,746,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in BioAge Labs during the fourth quarter worth about $1,058,000. Y Intercept Hong Kong Ltd acquired a new position in BioAge Labs during the first quarter worth about $3,521,000. Finally, Occudo Quantitative Strategies LP acquired a new position in BioAge Labs during the third quarter worth about $113,000.

BioAge Labs Price Performance

Shares of NASDAQ BIOA opened at $10.48 on Thursday. The company has a market cap of $481.03 million, a PE ratio of -4.40 and a beta of 0.93. BioAge Labs, Inc. has a 12 month low of $4.38 and a 12 month high of $25.95. The company has a 50-day simple moving average of $19.70 and a 200-day simple moving average of $18.98.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million for the quarter. On average, analysts anticipate that BioAge Labs, Inc. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BIOA. Needham & Company LLC reduced their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. BTIG Research restated a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a report on Monday, August 3rd. Roth Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.